Delgado VT, Carnot UJ, de Castro AR, Muñío PJ, Hernández CC, Núñez QA, Pérez RG, Rodríguez FY

Language: Spanish
References: 35
Page: 231-241
PDF size: 195.79 Kb.

ABSTRACT

A retrospective descriptive study was conducted in the Hematology Service at Hermanos Ameijeriras Hospital to know the causes of death in patients with Hodgkin lymphoma, who were treated from January 1983 to December 2008. Out of 619 patients diagnosed in that period, the total sample was formed by 443 patients. 287 (64.8 %) of them were alive at the end of the study, and 156 (35.2%) had died. This disease relapse/progression were the leading cause of death, regardless age of its presentation, treatment used, and the time of progression (125 patients, 80 %). The remaining 20 % of deaths occurred from secondary malignancies in 10 patients (6.4 %), complications of treatment in 8 (5.1 %), fatal infectious complications in 2 (1.2 %), and cardiovascular disease in 3 (1.9 %). In 8 patients (5.1 %) the cause of death was not stated. Secondary malignancies were predominant in patients aged 40-59, who received combined treatment with less than 10 years of evolution.

REFERENCES

1. Connors JM. Hodgkin's Lymphoma. En: Goldman L, Schafer AI, editores. Goldman's Cecil Medicine. 24a ed. New York: Elsevier Saunder; 2012. p. 1228-33.

2. Eichenauer DA, Engert A, Diehl V. Hodgkin Lymphoma: clinical manifestations, staging, and therapy. En: Hoffman R, Benz EJ, Leslie E. Silberstein LE, editores. Hematology: Basic Principles and Practice. 6a ed. Philadelphia: Elsevier Saunder; 2013. p. 1138-56.

3. Provencio M, Millán I, España P, Sánchez AC, Sánchez JJ, Cantos B, et al. Analysis of competing risks of causes of death an their variation over different time periods in Hodgkin's Disease. Clin Cancer Res. 2008;14:5300-5.

4. Goodman KA, Riedel E, Serrano V, Gulatin S, Moskowitz C,Yahalom J. Long-term effects of High dose chemotherapy and radiation for relapsed and refractary Hodgkin´s lymphoma. J Clin Oncology. 2008;26:5240-7.

5. Swerdlow A, Higgins C, Smith P, Cunningham D, Hancock BW, Horwich A, et al. Myocardial infarction mortality risk after treatment for Hodgkin´s disease. J Nat Cancer Inst. 2007;99:206-14.

6. Dores GM, Cote TR, Travis LB. New malignancies following Hodgkin lymphoma, non Hodgkin lymphoma and myeloma in SEER Cancer Registries. Nat Cancer Inst. 2006;5:5302-8.

7. Hodgson D, Gilbert E, Dores G, Schonfeld S, Lynch Ch, Storm H, et al. Long-term solid cancer risk among 5 years survivors of Hodgkin´s disease. J Clin Oncology. 2007;25:1489-97.

8. Castellino SM, Geiger AM, Mertens AC, Tooze JA, Goodman P, Stovall M, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2011;117:1806-16.

9. Ansell SM. Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematology. 2012;87:1096-103.

10. Ng AK, Chi R, Li S, Neuberg D, Fisher DC, Silver B, et al. A prospective study of pulmonary function in Hodgkin´s lymphoma patients. Ann Oncology. 2008;19:1754-8.

11. Aleman BM, Van Leeuwen FE, Klokman WJ, Van den Belt-Dusbout AW, Van t Veer MB, Bartelink H, et al. Long-term cause specific mortality of patients treated for Hodgkin's disease. J Clin Oncology. 2003;21:3431-9.

12. Thompson CA, Mauch K, Havyer R, Bhagra A, Kalsi H, Hayes SN, et al. Care of the adult Hodgkin's lymphoma survivor. Am J Med. 2011;124:1106-12.

13. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, De Braun M, van ´t Veer M, Baaijens M, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109:1878-86.

14. Meyer RM, Hoppe TR. Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy. Hematology Am Soc Hematol Educ Program. 2012; 2012:313-21.

15. Armitage JO. Early-Stage Hodgkin's Lymphoma. N Engl J Med. 2010;363:653-62.

16. Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, et al. Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study. J Clin Oncology. 2011;29:4096-104.

17. Straus DJ. Long-term survivorship at a price: late-term, therapy-associated toxicities in the adult Hodgkin lymphoma patient. Ther Adv Hematol. 2011;2:111-9.

18. Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncology. 2002;20:3484-94.

19. Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncology. 2002;20:2101-08.

20. Hodgson DC. Late Effects in the Era of Modern Therapy for Hodgkin Lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:323-9.

21. Crump M, Hodgson D. Secondary breast cancer in Hodgkin´s Lymphoma survivors. J Clin Oncology. 2009;27:4229-31.

22. Veit-Rubin N, Rapiti E, Usel M, Benhamou S, Vinh-Hung V, Vlastos G, et al. Risk, Characteristics, and Prognosis of Breast Cancer after Hodgkin's Lymphoma. The Oncologist. 2012;17:783-91.

23. Meyer R, Gospodarowicz M, Connors JM, Pearcey R, Bezjak A, Wells W, et al. Randomized comparison of ABVD chemotherapy with a strategy that incluyes radiation therapy in patients with limited stage Hodgkin´s Lymphoma: National Cancer Institute of Canada Clinical Trials Groupand the Eastern Cooperative Oncology Group. J Clin Oncology. 2005;23:4634-42.

24. Herbs C, Rehan FA, Brillant C, Bohlius J, Skoetz N, Schulz H, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin´s lymphoma: a systematic rewiew. Haematologica. 2009;95:494-500.

25. Franklin J, Pluetschow A, Paus M, Specht L, Aviles A, Biti G, et al. Second malignancy risk associated with treatment of Hodgkin´s lymphoma: meta- analysis of the randomized trials. Ann Oncology. 2006;17:1749-60.

26. Omer B, Kadan-Lottick NS, Roberts KB, Wang R, Demsky C, Kupfer GM, et al. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. Br J Haematology. 2012;158:615-25.

27. De Bruin ML, Sparidans J, van't Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: Lower risk after smaller radiation volumes. J Clin Oncology. 2009;27:4239-46.

28. Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematology. 2011;154:23-30.

29. Dunleavy K, Bollard CM. Sobering realities of surviving Hodgkin Lymphoma. Blood. 2011;117:1772-3.

30. Barbaro PM, Johnston K, Dalla-Poza L, Cohn RJ, Wang YA, Marshall GM, et al. Reduced incidence of second solid tumors in survivors of childhood Hodgkin's lymphoma treated without radiation therapy. Ann Oncol. 2011;22:2569-74.

31. Straus DJ, Portlock Carol S. Resultsof a prospective randomized clinical trial of doxorubicin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy versus ABVD alone for stages I, II and IIIA nonbulky Hodgkin disease. Blood. 2004;104:3483-9.

32. Sieniawski M, Reineke T, Nogova L, Jostin GA, Pfistner B, Diehl V, et al. Fertility in male patients with advanced Hodgkin lymphomatreated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood. 2008;111:71-76.

33. Ferme C, Eghbali H, Meerwaldt JH. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. New Eng J Med. 2007;357:1916-27.

34. Dabaja B, Cox JD, Buchhols TA. Radiation therapy can still be used safely in combined modality approaches in patients with Hodgkin's lymphoma. J Clin Oncology. 2007;25:3-5.

35. Huang MD, Xiaoxue MD, Jennifer MR, Rikka S, Kim L, Lee Y, et al. Juvenile Exposure to Anthracyclines Impairs Cardiac Progenitor Cell Function and Vascularization Resulting in Greater Susceptibility to Stress-Induced Myocardial Injury in Adult Mice. Circu Ame Heart Ass. 2010;121:615-6.